文献速递新发突发、热带与寄生虫病

监督与无监督伯氨喹根治间日疟和恶性疟:整群随机对照优效性试验

Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.
PubMed 文献 · Lancet Infect Dis · 2021-10-25

在印度尼西亚巴布亚地区开展整群随机对照优效性试验,比较监督与无监督伯氨喹根治方案对无并发症疟疾患者的疗效与安全性。共纳入419例患者,随访6个月,监督组间日疟复发风险显著低于无监督组,严重不良事件少且与治疗无关。

要点

  • 监督伯氨喹根治可降低间日疟复发风险。
  • 恶性疟患者中间日疟复发率监督组亦低于无监督组。

核心结论

  • 在中度疟疾传播地区,监督伯氨喹根治治疗降低了间日疟复发风险,且对恶性疟和间日疟患者均可见此效果。

研究设计与样本

  • 在印度尼西亚巴布亚开展整群随机对照开放标签优效性试验,21个村庄卫生站集群按年寄生虫指数匹配后1:1随机分配。
  • 纳入年龄>12个月、体重>5 kg、确诊无并发症恶性疟或间日疟患者,共筛查436例,入组419例。

主要发现

  • 监督组223例(11个集群),无监督组196例(10个集群);完成6个月随访者分别为161例(72%)和151例(77%)。
  • 报告7例严重不良事件(监督组3例,无监督组4例),均未判定与治疗相关,无死亡。

关键数值与推荐

  • 监督组患者隔日接受伯氨喹服药监督。
  • 随访6个月,复发患者以相同方案再治疗。

临床怎么用

  • 在间日疟和恶性疟共流行区,对无并发症疟疾患者可考虑采用监督方式给予伯氨喹根治以提高依从性并降低间日疟复发。
  • 监督模式可隔日进行,对治疗依从性差的患者可能获益。

局限性

  • 研究因性质无法设盲。
  • 监督组和无监督组分别有28%和23%的患者失访。
  • 结果来自中度传播地区,外推至其他共流行区需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a high risk of Plasmodium vivax recurrence in patients treated for Plasmodium falciparum malaria in co-endemic areas. Primaquine radical cure has the potential to reduce P vivax recurrences in patients presenting with P falciparum as well as P vivax malaria but is undermined by poor adherence to the currently recommended 14-day regimen. We aimed to assess the efficacy and safety of supervised versus unsupervised primaquine radical cure in patients presenting with uncomplicated malaria. METHODS: We did a cluster-randomised, controlled, open-label superiority trial in Papua, Indonesia. 21 clusters of village health posts, matched by annual parasite index, were randomly assigned (1:1) to treat patients (age >12 months and body weight >5 kg) presenting with confirmed uncomplicated P falciparum or P vivax malaria with oral dihydroartemisinin-piperaquine plus either a supervised or unsupervised 14-day course of oral primaquine (0·5 mg/kg per day). Patients in the supervised group were supervised taking their primaquine dose on alternate days. Patients were followed-up for 6 months and those who presented again with malaria were retreated with the same drug regimen. Masking was not possible due to the nature of the study. The primary outcome was the incidence risk of P vivax malaria over 6 months, assessed in the modified intention-to-treat population (all patients who were assigned to a treatment group, excluding patients who were lost to follow-up after their first visit). This trial is now complete, and is registered with ClinicalTrials.gov, NCT02787070. FINDINGS: Between Sept 14, 2016, and July 31, 2018, 436 patients were screened for eligibility and 419 were enrolled; 223 (53%) patients in 11 clusters were assigned to supervised primaquine treatment and 196 (47%) in ten clusters to unsupervised primaquine treatment. 161 (72%) of 223 patients in the supervised group and 151 (77%) of 196 in the unsupervised group completed 6 months of follow-up. At 6 months, the incidence risk of P vivax recurrence in the supervised group was 29·7% (95% CI 16·4-49·9) versus 55·8% (32·3-81·8) in the unsupervised group (hazard ratio 0·23 [95% CI 0·07-0·76]; p=0·016). The incidence rate for P vivax recurrence was 539 (95% CI 390-747) infections per 1000 person-years in the supervised group versus 859 (673-1096) in the unsupervised group (incidence rate ratio 0·63 [95% CI 0·42-0·94]; p=0·025). The corresponding rates in the 224 patients who presented with P falciparum malaria were 346 (95% CI 213-563) and 660 (446-977; incidence rate ratio 0·52 [95% CI 0·28-0·98]; p=0·043). Seven serious adverse events were reported (three in the supervised group, four in the unsupervised group), none of which were deemed treatment-related, and there were no deaths. INTERPRETATION: In this area of moderate malaria transmission, supervision of primaquine radical cure treatment reduced the risk of P vivax recurrence. This finding was apparent for patients presenting with either P falciparum or P vivax malaria. Further studies are warranted to investigate the safety and efficacy of radical cure for patients presenting with uncomplicated falciparum malaria in other co-endemic areas. FUNDING: The Bill & Melinda Gates Foundation, Wellcome Trust, and Department of Foreign Affairs and Trade of the Australian Government. TRANSLATION: For the Indonesian translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Poespoprodjo JR, Burdam FH, Candrawati F, et al. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet Infect Dis. 2021. PMID: 34710363. doi:10.1016/S1473-3099(21)00358-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。